BTG Limited
BTG was a United Kingdom-based specialist healthcare company focused on critical care, oncology and interventional medicine before its acquisition by Boston Scientific in 2019.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
BTG Limited was an international specialist healthcare company whose activities evolved from the commercialization of publicly funded research into the development, licensing and sale of medicines and interventional medical technologies. Its institutional roots lay in the National Research Development Corporation, established in 1948 to bring inventions arising from public research into practical use, and the National Enterprise Board, formed in 1975 as part of the United Kingdom government's industrial policy. These bodies were merged in 1981 to create the British Technology Group, a non-statutory organization intended to license and commercialize publicly developed technologies. The organization initially operated primarily as a technology-transfer and intellectual-property business. It acquired and licensed rights to inventions rather than concentrating only on manufacturing products itself. A significant early example was its 1983 commercialization agreement relating to magnetic resonance imaging. BTG subsequently licensed MRI technology to major industry participants, including General Electric and Philips, helping establish its reputation as an intermediary between publicly supported research and commercial healthcare markets. The company was placed on a statutory footing through the British Technology Group Act 1991, with HM Treasury initially serving as its sole shareholder. In March 1992, Cinven arranged a management buy-out from the United Kingdom government. BTG later became a publicly traded company through a London Stock Exchange flotation in 1995. On 27 May 1998, the British Technology Group adopted the name BTG, reflecting its development beyond a general technology-commercialization body and toward a more focused healthcare business. During the 2000s and 2010s, BTG increasingly emphasized specialty pharmaceuticals, critical-care treatments, oncology products and interventional medicine. The company combined internally developed products with acquisitions, licensing arrangements and royalty-generating partnerships. Its portfolio included antidotes and other critical-care medicines, oncology-related products, and catheter-based or image-guided technologies used in areas such as vascular disease, embolization and cancer treatment. This structure gave BTG several revenue channels: direct sales of specialty products, sales of interventional devices and royalties from products commercialized by partners. BTG expanded through a series of acquisitions. It completed the purchase of Protherics plc in December 2008, adding specialist pharmaceutical and biotechnology capabilities. In January 2011 it acquired Biocompatibles International plc, strengthening its position in drug-delivery and interventional oncology technologies. In May 2016 it acquired Israeli medical-device company Galil Medical for approximately US$110 million, adding minimally invasive cryoablation technologies. In September 2018 it agreed to acquire Novate Medical for up to approximately US$150 million, broadening its interventional cardiovascular pipeline. In November 2018, Boston Scientific announced an agreement to acquire BTG for approximately US$4.2 billion. The transaction was completed in August 2019. BTG therefore ceased to operate as an independent listed company and its businesses became part of Boston Scientific's broader medical-device and healthcare portfolio. The BTG name and legacy products continued to have relevance within the acquired businesses, but the standalone BTG corporate entity was no longer an independent public company.
History
BTG's history began with the United Kingdom's postwar effort to transfer publicly funded research into commercial use. The National Research Development Corporation was established in 1948 to commercialize inventions generated through public research. A second institution, the National Enterprise Board, was created in November 1975 to support the government's policy of moving public-sector industrial activity toward commercial ownership and operation. In 1981, the two organizations were merged to form the British Technology Group. The British Technology Group initially functioned chiefly as a licensing and technology-commercialization organization. Rather than operating primarily as a conventional pharmaceutical manufacturer, it sought intellectual-property rights and commercial partners for technologies developed through publicly supported research. Its agreement to commercialize magnetic resonance imaging technology in 1983 became one of its most notable early activities. BTG subsequently licensed MRI-related technology to companies including General Electric and Philips, illustrating the group's role in connecting research innovations with global medical-technology manufacturers. The organization was placed on a statutory basis under the British Technology Group Act 1991. HM Treasury was initially its only shareholder. In March 1992, Cinven arranged a management buy-out from the government, beginning BTG's transition into a privately owned commercial enterprise. The company then floated on the London Stock Exchange in 1995. On 27 May 1998, it changed its name from British Technology Group to BTG, a rebranding that accompanied its increasing concentration on healthcare commercialization and product development. Over the following two decades, BTG developed from a broad licensing organization into a specialist healthcare company. Its business combined specialty pharmaceutical products, interventional medical devices and royalties from products developed or sold with partners. Critical-care and oncology became important therapeutic areas, while its interventional-medicine operations addressed image-guided procedures, vascular disease, embolization and cancer treatment. The company used acquisitions to accelerate entry into adjacent technologies and to build a portfolio spanning both pharmaceuticals and devices. BTG completed the acquisition of Protherics in December 2008 and Biocompatibles International in January 2011. These transactions expanded its specialty-pharmaceutical, biotechnology and drug-delivery capabilities. In May 2016, BTG bought Galil Medical, an Israeli company focused on minimally invasive cryoablation systems, for approximately US$110 million. In September 2018, it agreed to acquire Novate Medical for up to approximately US$150 million, adding another interventional-medical-technology business. The company's independent existence ended after Boston Scientific announced in November 2018 that it would acquire BTG for approximately US$4.2 billion. The transaction was completed in August 2019. BTG had been a constituent of the FTSE 250 Index before the acquisition. Following completion, its operations were absorbed into Boston Scientific, leaving BTG as a legacy healthcare brand and former corporate group rather than an independent listed company.
- 2019
BTG is acquired by Boston Scientific
[1]Boston Scientific completed its acquisition of BTG in August 2019, ending the company's independent listed status.
- 2018
Novate Medical acquisition is announced
[1]BTG announced an agreement to acquire Novate Medical for up to approximately US$150 million.
- 2016
Galil Medical is acquired
[1]BTG acquired Galil Medical, expanding its minimally invasive cryoablation and interventional oncology capabilities.
- 2011
Biocompatibles International acquisition is completed
[1]BTG completed the acquisition of Biocompatibles International plc.
- 2008
Protherics acquisition is completed
[1]BTG completed its acquisition of Protherics plc.
- 1998
British Technology Group adopts the BTG name
[1]The company changed its name to BTG on 27 May 1998 as it focused more closely on healthcare technologies and products.
- 1995
London Stock Exchange flotation
[1]BTG became a publicly traded company on the London Stock Exchange.
- 1992
Management buy-out from the United Kingdom government
[1]Cinven arranged a management buy-out, moving BTG toward private commercial ownership.
- 1991
British Technology Group Act places the organization on a statutory footing
[1]The organization became a statutory body under United Kingdom legislation, with HM Treasury initially as its sole shareholder.
- 1983
MRI commercialization rights are acquired
[1]BTG obtained commercialization rights related to magnetic resonance imaging and later licensed technology to major manufacturers including General Electric and Philips.
Products and positioning
A specialist healthcare platform combining critical-care and oncology pharmaceuticals with interventional medicine technologies, supported by licensing, partnerships and targeted acquisitions.
Critical-care pharmaceutical
CroFab
CroFab was one of BTG's specialist critical-care medicines. It is an antivenom product associated with the treatment of certain North American pit-viper snake envenomations and represented BTG's focus on highly specialized hospital therapies.
Critical-care pharmaceutical
DigiFab
DigiFab was a specialist antidote used in hospital critical-care settings for poisoning or toxicity associated with digoxin and related cardiac glycosides. It formed part of BTG's portfolio of targeted emergency medicines.
Oncology supportive-care medicine
Voraxaze
Voraxaze is a recombinant enzyme therapy used to reduce toxic methotrexate concentrations in defined emergency clinical situations. It exemplified BTG's strategy of serving specialized oncology and critical-care needs with narrowly targeted products.
Interventional oncology
TheraSphere
TheraSphere is an image-guided radioembolization technology used in interventional oncology. The product delivers radioactive microspheres through the arterial blood supply to selected liver tumors and was part of BTG's oncology-focused medical-technology portfolio.
Catheter-based vascular therapy
EKOS
EKOS refers to a catheter-based system used in interventional vascular procedures, including directed delivery of therapies in selected clot-treatment settings. It represented BTG's broader interventional-medicine business and its emphasis on minimally invasive, image-guided care.
Interventional oncology device
Galil Medical cryoablation systems
Galil Medical's technologies used controlled freezing to ablate targeted tissue through minimally invasive procedures. BTG acquired the company in 2016, adding cryoablation capabilities to its interventional oncology and image-guided treatment portfolio.
Brand decisions
2018
Agree to acquire Novate MedicalM&ABackground
BTG continued to broaden its interventional medicine portfolio through targeted acquisitions.
Action taken
BTG agreed to acquire Novate Medical for consideration of up to approximately US$150 million.
Aftermath
The transaction extended BTG's interventional cardiovascular technology activities shortly before the company was acquired by Boston Scientific.
Maximum acquisition consideration. Up to approximately US$150 million (September 2018)
2018
Agree to be acquired by Boston ScientificM&ABackground
BTG had built a portfolio spanning specialty pharmaceuticals, critical care, oncology and interventional medicine.
Action taken
Boston Scientific announced an agreement to acquire BTG for approximately US$4.2 billion.
Aftermath
The acquisition was completed in August 2019, ending BTG's independent status and incorporating its businesses into Boston Scientific.
Announced acquisition value. Approximately US$4.2 billion (November 2018 announcement)
2016
Acquire Galil MedicalM&ABackground
BTG sought to expand its interventional oncology and minimally invasive treatment capabilities.
Action taken
BTG acquired Galil Medical for approximately US$110 million.
Aftermath
The transaction added cryoablation technologies and strengthened BTG's position in image-guided oncology procedures.
Acquisition consideration. Approximately US$110 million (May 2016)
1998
Rebrand as BTG and focus on healthcareStrategyBackground
The former British Technology Group had evolved from a broad public-research commercialization organization into a commercially oriented healthcare company.
Action taken
On 27 May 1998, the company adopted the BTG name and concentrated its activities more closely on developing, licensing and commercializing medical innovations.
Aftermath
The reorientation established the BTG identity used during the company's later expansion into specialty pharmaceuticals and interventional medicine.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/btg-limited · Editorial policy · How profiles are compiled